Table 4.
Multivariate survival analysis.
| Total (n = 131) |
Postmenopausal Women (n = 86) |
Men over 40 years of age (n = 45) |
||||
|---|---|---|---|---|---|---|
| Adjusted hazard ratio | 95% CI | Adjusted hazard ratio | 95% CI | Adjusted hazard ratio | 95% CI | |
| FRAX (continuous, log-transformed) | 2.26 | 1.52–3.38 | 2.41 | 1.45–3.99 | 3.21 | 1.03–9.98 |
| Bisphosphonate comparison subjects | 1 | (reference) | 1 | (reference) | 1 | (reference) |
| Bisphosphonate prescription group | 0.84 | 0.45–1.54 | 0.67 | 0.31–1.44 | 1.21 | 0.41–3.54 |
| Active Vitamin D comparison subjects | 1 | (reference) | 1 | (reference) | 1 | (reference) |
| Active Vitamin D prescription group | 0.82 | 0.47–1.43 | 0.72 | 0.36–1.44 | 1.27 | 0.40–3.87 |
| No methylprednisolone pulse treatment | 1 | (reference) | 1 | (reference) | 1 | (reference) |
| Methylprednisolone pulse treatment group | 1.14 | 0.61–2.13 | 1.68 | 0.79–3.61 | 0.4604 | 0.13–1.69 |
| No prior high-dose GC treatment | 1 | (reference) | 1 | (reference) | 1 | (reference) |
| Prior high-dose GC treatment | 2.49 | 1.18–5.28 | 1.24 | 0.43–3.60 | 3.46 | 1.12–10.73 |
Adjusted by bisphosphonate, vitamin D, or mPSL pulse therapy, a history of high-dose GC, and FRAX score.